Tag: Baylor College of Medicine

ebrahim s delpassand md facnm

FDA Approves Amendment for PRRT Clinical Trial in Texas

August 2, 2012

BREAKING NEWS:  The Food and Drug Administration (FDA) has just approved the RadioIsotope Therapy of America (RITA) Foundation’s amendment to the Investigational New Drug (IND) protocol for intra-hepatic artery administration of Lu-177 Octreotate

READ MORE
glucomedix1

RadioMedix $2.8 Million Grant from Texas Emerging Technology Fund to Result in New Products that Benefit Carcinoid and Neuroendocrine Cancer Patients

March 23, 2011

Two innovative products that will enable users to generate and label PET radiotracers on-site at a significantly reduced cost will be developed by RadioMedix, Inc. with a $2.8 million grant from the Texas Emerging Technology Fund.  According to Ebrahim

READ MORE
ebrahim s delpassand md facnm

FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)

August 24, 2010

For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…

READ MORE
robert f gagel md4

Multiple Endocrine Neoplasias (MEN) Patient Education Conference to Be Held at MD Anderson Cancer Center in June

April 26, 2010

MEN, carcinoid, and neuroendocrine tumor patients, family members, advocacy groups, physicians, and caregivers are invited to attend MD Anderson Cancer Center’s Multiple Endocrine Neoplasias Patient Education Conference on Saturday, June 26,

READ MORE